SCHEMBL6038667

SCHEMBL6038667

CC(C)c1ccc(S(=O)(=O)Nc2nc3ccccc3nc2OCc2cccnc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
KDM4E B2RXH2 3/20 0.53
LMNA P02545 1/20 0.53
HSD17B10 Q99714 1/20 0.53
NPSR1 Q6W5P4 1/20 0.49
CCR4 P51679 1/20 0.48
SCN9A Q15858 1/20 0.47
HRH4 Q9H3N8 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
ADAMTS4 O75173 1/20 0.44
ADRB2 P07550 2/20 0.43
ADRB1 P08588 2/20 0.43
ADRB3 P13945 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NAMPT P43490 1/20 0.43
IDO1 P14902 1/20 0.42
TRPV1 Q8NER1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038817 0.89 MEN1 (0.57) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038804 0.89 MEN1 (0.66) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038910 0.89 KDM4E (0.56) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6039136 0.89 KDM4E (0.63) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038395 0.88 KDM4E (0.57) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038465 0.87 KDM4E (0.54) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6039075 0.87 KDM4E (0.53) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038408 0.87 MEN1 (0.62) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038697 0.86 LMNA (0.55) MEN1KMT2AKDM4ELMNAHSD17B10
SCHEMBL6038733 0.86 SCN9A (0.50) MEN1KMT2ALMNACCR4SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 MEN1 2431/4885KMT2A 4190/4885KDM4E 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.